Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication-Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study.


Por: Montesinos P, Rodríguez-Veiga R, Bergua JM, Algarra Algarra JL, Botella C, Rodríguez-Arbolí E, Bernal T, Tormo M, Calbacho M, Salamero O, Serrano J, Noriega V, López-López JA, Vives S, López-Lorenzo JL, Colorado M, Vidriales MB, García Boyero R, Olave MT, Herrera Puente P, Arce O, Barrios M, Jose Sayas M, Polo M, Gómez-Roncero MI, Barragán E, Ayala R, Chillón C, Calasanz MJ, Paiva B, Boluda B, Casas-Avilés I, Lloret-Madrid P, Sánchez MJ, Rodríguez-Medina C, Cuevas L, Raposo-Puglia JÁ, Mateos MC, Olivares M, Martínez-Chamorro C, Alonso N, Suárez S, Sánchez-Vadillo I, Solé Rodríguez M, González BJ, Martínez-Francés A, Cuello R, Fernández A, Martínez-Cuadrón D and Labrador J

Publicada: 1 ene 2026 Ahead of Print: 13 oct 2025
Resumen:
PURPOSE: Quizartinib, an oral, selective, second-generation, type-II FMS-like tyrosine kinase 3 (FLT3) inhibitor with high binding affinity to internal tandem duplication (ITD) and wild-type (WT) FLT3, has shown early clinical activity as monotherapy in patients with relapsed/refractory FLT3-ITD-negative AML. The phase III QuANTUM-First trial showed that quizartinib significantly prolonged survival versus placebo when added to standard chemotherapy, followed by single-agent maintenance, in patients with newly diagnosed (ND) FLT3-ITD-positive AML. We investigated the safety and efficacy of quizartinib in patients with ND FLT3-ITD-negative AML. METHODS: The phase II, randomized, double-blind, placebo-controlled QUIWI trial enrolled patients age 18-70 years with ND FLT3-ITD-negative (mutant-to-WT allelic ratio <0.03) AML. Patients were randomly assigned 2:1 to receive standard induction and consolidation chemotherapy combined with either quizartinib 60 mg once daily or placebo, followed by single-agent maintenance with quizartinib or placebo. The primary end point was event-free survival (EFS). Secondary end points included overall survival (OS) and safety. RESULTS: Overall, 273 patients were randomly assigned to quizartinib (n = 180) or placebo (n = 93). At data cutoff, median EFS was 20.4 months and 9.9 months in the quizartinib and placebo arms, respectively (P = .046). Median OS was not reached and 29.3 months in the quizartinib and placebo arms, respectively (P = .012); 3-year OS rates were 60.8% and 45.7%. The most frequently reported adverse events (any grade) were fever, rash, diarrhea, and mucositis. CONCLUSION: The addition of quizartinib to standard chemotherapy was associated with significantly longer EFS and OS than placebo in patients with ND FLT3-ITD-negative AML.

Filiaciones:
Montesinos P:
 Hospital Universitari i Politècnic La Fe, Valencia, Spain

Rodríguez-Veiga R:
 Hospital Universitari i Politècnic La Fe, Valencia, Spain

Bergua JM:
 Hospital San Pedro de Alcántara, Cáceres, Spain

Algarra Algarra JL:
 Hospital General de Albacete, Albacete, Spain

Botella C:
 Hospital General Universitario de Alicante, Alicante, Spain

Rodríguez-Arbolí E:
 Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS)/CSIC, Universidad de Sevilla, Sevilla, Spain

Bernal T:
 Instituto de Investigación Sanitaria del Principado de Asturias and Instituto Universitario de Oncología del Principado de Asturias, Hospital Universitario Central de Asturias, Oviedo, Spain

Tormo M:
 Hospital Clínico Universitario de Valencia, INCLIVA Biomedical Research Institute, Valencia, Spain

Calbacho M:
 Hospital Universitario 12 de Octubre, Madrid, Spain

Salamero O:
 University Hospital Vall d'Hebron, and Experimental Hematology, Vall d'Hebron Institute of Oncology, Barcelona, Spain

Serrano J:
 Hospital Universitario Reina Sofia, IMIBIC, UCO, Córdoba, Spain

Noriega V:
 Hospital Universitario de A Coruña, A Coruña, Spain

López-López JA:
 Hospital Universitario de Jaén, Jaén, Spain

:
 ICO-Hospital Germans Trias i Pujol-ICO, Institut de Recerca Josep Carreras, Badalona, Spain

López-Lorenzo JL:
 Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain

Colorado M:
 Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

Vidriales MB:
 Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain

García Boyero R:
 Hospital General Universitario de Castellón, Castellón de la Plana, Spain

Olave MT:
 Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain

Herrera Puente P:
 Hospital Universitario Ramón y Cajal, Madrid, Spain

Arce O:
 Hospital Universitario Basurto, Bilbao, Spain

Barrios M:
 Hospital Universitario Regional de Málaga, Málaga, Spain

Jose Sayas M:
 Hospital Universitario Doctor Peset, Valencia, Spain

Polo M:
 Hospital Clínico San Carlos, Madrid, Spain

Gómez-Roncero MI:
 Hospital General Universitario de Toledo, Toledo, Spain

Barragán E:
 Hospital Universitari i Politècnic La Fe, Valencia, Spain

Ayala R:
 Hospital Universitario 12 de Octubre, Madrid, Spain

Chillón C:
 Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain

Calasanz MJ:
 Cancer Center Clinica Universidad de Navarra (CCUN), Centro de Investigacion Medica Aplicada, Universidad de Navarra (CIMA), IDISNA, CIBER-ONC CB16/12/00369, Pamplona, Spain

Paiva B:
 Cancer Center Clinica Universidad de Navarra (CCUN), Centro de Investigacion Medica Aplicada, Universidad de Navarra (CIMA), IDISNA, CIBER-ONC CB16/12/00369, Pamplona, Spain

Boluda B:
 Hospital Universitari i Politècnic La Fe, Valencia, Spain

Casas-Avilés I:
 Hospital San Pedro de Alcántara, Cáceres, Spain

Lloret-Madrid P:
 Hospital Universitari i Politècnic La Fe, Valencia, Spain

Sánchez MJ:
 Hospital Universitario Lucus Augusti, Lugo, Spain

Rodríguez-Medina C:
 Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain

Cuevas L:
 Hospital Universitario Araba-Txagorritxu, Araba, Spain

Raposo-Puglia JÁ:
 Hospital Universitario Puerta del Mar, Cádiz, Spain

Mateos MC:
 Hospital Universitario de Navarra, Navarra, Spain

Olivares M:
 Hospital Galdakao-Usansolo Ospitalea, Bizkaia, Spain

Martínez-Chamorro C:
 Hospital Universitario Quirónsalud Madrid and European University of Madrid, Madrid, Spain

Alonso N:
 University Hospital of Santiago de Compostela, IDIS, Santiago de Compostela, Spain

Suárez S:
 Complejo Hospitalario Universitario de Vigo, Vigo, Spain

Sánchez-Vadillo I:
 Hospital Universitario La Paz, Madrid, Spain

Solé Rodríguez M:
 Hospital Universitario Juan Ramón Jiménez, Huelva, Spain

González BJ:
 Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain

Martínez-Francés A:
 Hospital General Universitario Santa Lucía, Murcia, Spain

Cuello R:
 Hospital Clínico Universitario de Valladolid, Valladolid, Spain

Fernández A:
 Hospital Universitario Virgen de la Victoria, Málaga, Spain

Martínez-Cuadrón D:
 Hospital Universitari i Politècnic La Fe, Valencia, Spain

Labrador J:
 Hospital Universitario de Burgos, Burgos, Spain
ISSN: 0732183X





JOURNAL OF CLINICAL ONCOLOGY
Editorial
American Society of Clinical Oncology, 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA, Estados Unidos America
Tipo de documento: Article
Volumen: 44 Número: 1
Páginas: 42-53
WOS Id: 001645471000004
ID de PubMed: 41082703
imagen Green Submitted, hybrid

MÉTRICAS